Loading
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.
Previous close
$3.27
−$0.02 · -0.61%
After-hours
$3.2513
−$0.0187 · -0.57%
Sep 11, 7:48 PM ET
Regular session · ET · Market data may be delayed.
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.
Day range
Current $3.27
52-week range
Current $3.27
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
42
Fair Value
Sentiment
59
Mixed
Risk
54
Elevated Risk
Momentum
34
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.
Day range
Current $3.27
52-week range
Current $3.27
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 41K USD | 20K USD | 426K USD | −68K USD | 4.41M USD |
| Gross profit | 41K USD | 20K USD | 426K USD | −68K USD | 4.41M USD |
| Research and development | 66.43M USD | 82.23M USD | 65.8M USD | 70.54M USD | 74.54M USD |
| Selling, general, and administrative | 28.1M USD | 20.97M USD | 18.14M USD | 17.13M USD | 15.41M USD |
| Operating expenses | 94.53M USD | 103.19M USD | 96.36M USD | 87.67M USD | 101.32M USD |
| Interest income | 7.54M USD | 8.07M USD | 7.35M USD | 2.87M USD | 203K USD |
| Interest expense | 1.64M USD | 9K USD | 35K USD | 8K USD | 5K USD |
| Depreciation and amortization | 112K USD | 238K USD | 477K USD | 493K USD | 551K USD |
| Operating income | −94.49M USD | −103.17M USD | −95.93M USD | −87.74M USD | −96.91M USD |
| Net income | −88.09M USD | −95.06M USD | −88.45M USD | −84.71M USD | −97.09M USD |
Company facts updated Sep 12, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
Average target
$6.25
91.13% upside| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Feb 6, 2017 | $291Monthly | Jan 24, 2017 | — |
Dividend | Jan 20, 2017 | $291Monthly | Jan 24, 2017 | Feb 3, 2017 |
Ex-dividend Feb 6, 2017
$291
Monthly
Record Jan 24, 2017
Ex-dividend Jan 20, 2017
$291
Monthly
Record Jan 24, 2017 · Payment Feb 3, 2017
Funds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR S&P Biotech ETFXBI28.51M0.26%10.57B USD0.35%$156.2-0.40%
iShares Russell 2000 ETFIWM16.87M0.02%77.55B USD0.19%$288.89+0.41%
Vanguard Morningstar Total Stock Market ETFVTI16.33M0.00%2.3T USD0.03%$376.31+0.82%
Vanguard Extended Market ETFVXF6.36M0.01%93.7B USD0.05%$237.76+0.68%
iShares Russell 2000 Value ETFIWN6.22M0.04%14.28B USD0.24%$219.69+0.33%
iShares Biotechnology ETFIBB4.73M0.05%10.3B USD0.44%$202.93+0.14%
Fidelity Enhanced Small Cap ETFFESM4.64M0.07%6.49B USD0.28%$46.36+0.78%
Vanguard Russell 2000 ETFVTWO3.17M0.02%17.4B USD0.06%$116.76+0.36%State Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Russell 2000 Value ETFIWNiShares Biotechnology ETFIBBFidelity Enhanced Small Cap ETFFESMVanguard Russell 2000 ETFVTWOAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
